The Latest Breaking News from Ionis Pharmaceuticals

Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

A Relative Strength Rating upgrade for Ionis Pharmaceuticals shows improving technical performance.

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Ionis Pharmaceuticals kept its 2022 outlook intact Tuesday despite a broad second-quarter miss. But IONS stock tumbled.

The IBD SmartSelect Composite Rating for Ionis Pharmaceuticals increased from 94 to 96 Friday.

 

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

  Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.